AbbVie Gets CHMP Positive Opinion for Rinvoq in Rheumatoid Arthritis

Date : 10/18/2019 @ 12:22PM
Source : Dow Jones News
Stock : AbbVie Inc (ABBV)
Quote : 87.2  -1.82 (-2.04%) @ 9:30PM
After Hours
Last Trade
Last $ 87.20 ◊ 0.00 (0.00%)

AbbVie Gets CHMP Positive Opinion for Rinvoq in Rheumatoid Arthritis

Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more AbbVie Charts.

By Michael Dabaie


AbbVie Inc. (ABBV) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Rinvoq for the treatment of adult patients with moderate to severe active rheumatoid arthritis.

The CHMP positive opinion is supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, AbbVie said. The opinion will now be referred to the European Commission for final approval, the company said.

In Phase 3 trials, upadacitinib improved signs and symptoms of rheumatoid arthritis, inhibited radiographic progression and improved physical function, AbbVie said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

October 18, 2019 08:07 ET (12:07 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.